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1. Introduction 2. Materials and methods 
Human interferons (IFNs) are currently being pro- 
duced in bacteria fter genetic manipulation [ 1,2]. 
Since these IFNs may eventually be used in a clinical 
context, it is essential to determine whether their 
action on human cells is identical to that of conven- 
tional IFN. Although bacterially produced IFNs have 
been shown to have antiviral effects [2,3], other 
aspects of IFN action have not been fully explored. 
2.1. Peripheral lymphocytes 
Peripheral lymphocytes were obtained from hepa- 
rinized blood of normal donors by nylon column 
adsorption and Ficoll-Hypaque sedimentation as in 
[5], Resting cells were cultivated at lO”/ml in RPMI- 
1640 medium supplemented with 10% autologous 
plasma, 50 U/ml penicillin, 50 j.&nl streptomycin, at 
37’C in 7% COa atmosphere. 
In previous work we have shown that resting human 
peripheral blood T-lymphocytes, when exposed to 
interferon, exhibit enhanced synthesis of a set of eight 
specific peptides (I-peptides) [4]. This response is
detectable within 6 h of IFN treatment and occurs 
with cells of all normal donors examined e30 to 
date). Both 1FN-o and IFNQ elicit the same response. 
The specificity and complexity of this response to 
conventionally induced IFNs suggests hat it may be 
a useful indicator of the ability of IFNs of more exotic 
origin to produce the same spectrum of effects as the 
conventional forms. This communication describes 
the I-peptide enhancement obtained in human lym- 
phocytes using virtually pure IFN-cQ, produced by E. 
coli carrying a plasmid containing the cloned cDNA 
for that IFN species. We found the IFN-u, was capable 
of enhancing synthesis of the same 8 peptides as pre- 
viously reported. However, unlike conventionally 
induced IFN, the bacterially synthesized material did 
not produce this effect in all donors. This may reflect 
the complexity of the IFN-ar’s, which derive from at 
least 8 naturally occurring enes, so that a single com- 
ponent of the usual mixture may exhibit a limited 
range of donor or cell-type specificities. 
2.2. Labeling of proteins 
Portions containing 2 X 10’ cells were incubated 
at 5 X 106/ml in RPMI-1640 lacking leucine, with 
150 @i/ml [3H]leucine (Amersham, 60 Ci/mmol), 
for 4 h. Cells were then washed with cold phosphate- 
buffered (0.02 M, pH 7.4) isotonic saline and lysed by 
resuspension in 200 fl of 9.5 M urea, 2% NonidetP40, 
5% 2.mercaptoethanol, 2% LKB ampholytes (pH 
3.5-10). After vortexing for 10 s, nuclear esidue was 
removed by centrifugation and the sample was stored 
at -8O’C. 
2.3. Two-dimensional electrophoresis 
Samples containing l-2 X lo6 cpm were analyzed 
by 2.dimensional e ectrophoresis, asin [6]. Second 
dimension gels were 12% acrylamide. Gels were fixed, 
stained and dried as in [6] and fluorographs oflabeled 
proteins were prepared as in [4]. 
2.4. Interferon preparations 
+ Address for correspondence: Building 10 Room 5B36, 
National Institutes of Health, Bethesda, MD 20205, USA 
The conventional 1FN-o preparation used was lym- 
phoblastoid IFN from Wellcome Laboratories, induced 
in Namalva cells by Sendai virus and partially purified 
[7] to a specific activity of 1.5 X lo6 IU/mg protein. 
This preparation has been estimated to have <5% 
contamination with IFNj?, the remainder of the activ- 
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Fig.1. Effect of various IFNs on I-peptide synthesis in lymphocytes. Aliquots of resting lymphocytes containing 2 X 10’ cells 
were incubated with 100 HI/ml of IFN for 2 h. Cells were then labeled in the presence of IFN for 4 h with [ ‘Hlleucine. Cell 
lysates were then prepared and analyzed by Zdimensional electrophoresis in polyacrylamide gels. First dimension (isoelectric 
focussing) was in 4.5% acrylamide (19:l acrylamide:bisacrylamide), 9 M urea, 2% NP 40 and 2% (w/v) LKB ampholytes (pH : 
10) for 9000 V. h. Second dimension was in 12% a&amide (36: 1 acrylamide:bisacrylamide) 0.1% SDS, support buffer 0.38 
Tris-glychre (pH 8.3) for 23 h at 4.5 W, constant power. Fixation and fluorography were as in [4]. Fluorographs are shown: 
(A) Control; (B) IFNQ; (c) IFNay; (D) IFNes. I-peptides [ 1 I are circled, and enumerated in (B). 
3..5- 
M 
110 
Volume 140, number 1 FEBS LETTERS April 1982 
ity identifiable immunologically as IFN-cr (leukocyte 
IFN) [4]. The IFNQ preparation was fibroblast IFN, 
induced by poly(I):poly(C) in FS-4 fibroblasts [8] and 
was the generous gift of Dr E. Knight of E. I. DuPont. 
Its specific activity was >lO’ IU/mg protein. Bacte- 
rially produced IFNq was kindly provided by Drs 
M. Fountoulakis and C. Weissmann, Zurich, at a spe- 
cific activity of 1.5 X IO* IU/mg of protein. It was 
produced in E. coli carrying a modified IFN&s cDNA 
[9] and was purified as in [3]. A polyacrylamide gel 
electrophoretic analysis, provided with the sample, 
showed this material to have a single major band and 
several faint minor bands. 
3. Results 
Freshly prepared lymphocytes from unselected 
normal donors were exposed to various IFN prepara- 
tions for 6 h and the proteins ynthesized uring the 
final 4 h of incubation were analyzed by2.dimensional 
electrophoresis. 
Treatment with conventional IFNa and IFNQ at 
100 U/ml produced enhanced synthesis of the same 
set of I-peptides as report in [4] (fig.1 A-C). 
Of the set of I-peptides usually seen, peptides I-6 
and I-7 are the most difficult to detect and document 
photographically. However, enhanced synthesis of 
these peptides was detected on the original fluoro- 
graphs in all IFN-treated samples. We have shown that 
such visual judgements can be made reliably when 
labeling of a peptide has increased 2-fold or more 
relative to its neighbor peptides [4]. 
Exposure to bacterially produced IFN-ars at the 
same concentration as conventional IFNs (100 U/ml), 
produced an identical enhancement of I-peptide syn- 
thesis (flg.lD). Apart from the I-peptide response, no 
other alterations, produced specifically by IFNaz, 
were detected. Thus IFN-os produced by bacteria can 
elicit a complex biochemical response from normal 
human cells, freshly isolated from the body, indistin- 
guishable from their response to conventional IFNs. 
Repetition of this experiment, however, revealed 
that the lymphocytes of some donors responded only 
minimally to IFNq, in terms of I-peptide synthesis, 
while showing the usual prominent response to IFNQ. 
Thus, the lymphocytes of the donor analyzed in 
fig.2 revealed abarely detectable response to IFNq, 
most easily detected by comparison of peptide I-l 
with the control preparation (fig2A,B). The other 
I-peptides were also very slightly enhanced, although 
photographic reproduction renders documentation 
difficult. These cells responded strongly to IFNQ, 
however (fig2C). 
This donor’s 2.dimensional protein map, interest- 
ingly, presents an apparent genetic variant, evident as 
a relatively heavily-labeled peptide which obscures 
protein I-6 in both control and IFN-treated samples. 
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Fig.2. Ipeptide synthesis in a donor showing reduced respon- 
siveness to IFN+. Conditions as in fi.1: (A) Control; (B) 
IFN-or,; (C) IFN_P. In this donor, peptide I-6 was obscured by 
another more heavily labeled peptide which migrates to nearly 
the same position. 
111 
Volume 140, number 1 FEBS LETTERS April 1982 
4. Discussion 
The IFN concentration used in this study (100 IU/ 
ml), has never previously failed to elicit a maximal 
I-peptide response, using conventional 1FN-o or IFN_P. 
Therefore, we conclude that IFN-~L, produced in bac- 
teria, although capable of eliciting a typical I-peptide 
response, shows a degree of selectivity among lym- 
phocytes of different normal donors not found with 
conventional IFNs. Such selectivity is not entirely 
unexpected. At least 8 1FN-o genes, each producing 
a slightly different product, have been identified 
[ lo,1 11, while only one or two IFNQ genes have been 
detected [121. Different degrees of cross-species viral 
protection have been reported for two of the IFN-o’s 
[9], a finding which may have the same origin as the 
selectivity seen here. 
When IFN-ars induced an I-peptide response, all 
eight peptides were enhanced as a group; the reduced 
response similarly encompassed the complete set. 
This suggests a coordinate response to the initiating 
stimulus which is, presumably, the binding of a recep- 
tor site. Differences in response to different IFN-o’s, 
then, may reflect genetic or functional heterogeneity 
of the receptor. The various IFN&, as a group, may 
recognize the entire receptor ange, with each member 
adapted to a segment of that range. IFN_P, apparently, 
recognizes the entire receptor ange, since no donor 
in our experience has failed to respond. Further expe- 
rience with other members of the 1FN-o complex, as 
they become available in sufficient quantity and 
purity, should clarify the question of receptor ange 
recognition. 
Previously, bacterially produced cw-IFNs have shown 
antiviral activity [2,3] of comparable fficiency to 
that of conventional 1FN-o [3]. The present report 
provides evidence that the complex biological response 
involved in controlling the synthesis of 8 specific pep- 
tides in human lymphocytes i  also equivalent for 
bacterially produced and conventional IFNs. This 
increases the likelihood that bacterially produced IFNs 
will be an acceptable and potentially more available 
alternative to conventional IFNs. Such evidence of 
equivalent physiological ctivity is especially impor- 
tant in view of the recent demonstration that conven- 
tional IFN-omay lack some 10 COOH-terminal mino 
acids predicted from the sequence analysis of DNA 
clones used to direct IFN synthesis by bacteria [131. 
The results reported here suggest the usefulness of
this approach in screening potential recipients of IFN 
for clinical purposes, to determine responsiveness and 
to estimate sensitivity by using limiting IFN concen- 
trations. The numbers of lymphocytes needed for 
such studies can be obtained from patients without 
risk and the amounts of IFN needed are small (<2000 
units/test). Since the lymphocytes are used immedi- 
ately, without exposure to extended in vitro cultiva- 
tion or to heterologous materials (autologous plasma, 
or serum-free conditions may be used), the most 
direct approach to individual cellular response i  
afforded without any patient risk. 
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